Europe Jet Fuel Deficit Drives South Korean Imports to Four-Year High 
Trump Bans CNN, MS NOW and Politico From White House 
fnny Beta Launches With a Simple Idea: Find an Event, Show Up, Get Rewarded 
SoftBank Launches $11 Billion Bond Sale to Fund OpenAI Investment 
RBA Says ASX Still Falls Short on Governance and Risk Controls 
US-China Talks Target AI, Tariffs Ahead of Trump-Xi Summit 
White House Bars CNN, MS NOW and Politico Reporters 
US Northeast Airports Resume Operations After Telecom Outage Disrupts Thousands of Flights 
OpenAI Urges US-Led Global Standards for Frontier AI 
Nike Earnings at Risk as UBS Cuts Price Target to $42 
Yen in Focus as BOJ, Fed Rate Hikes Reshape Currency Markets 
Hyundai CEO Warns Chinese Automakers Could Disrupt US Market 
Wall Street Surges as Meta Leads AI Rally, Oil Prices Fall 
Gold Prices Rise as Oil Slide Eases Fed Rate Hike Fears 
Trump Plans Federal AI Force and AI Czar 
France Debt-to-GDP Ratio Seen Hitting Record 119.3% in 2026 
Add as a preferred source on Google
Celltrion, a South Korean pharmaceutical company, revealed on Thursday, Aug. 12, that it has received emergency approval from the government of Brazil for its COVID-19 antibody treatment.
According to The Korea Herald, Celltrion shared that the Health Regulatory Agency of the said country granted emergency use authorization (EUA) for its Regkirona or CT-P59, which is a COVID-19 treatment. It was said that the agency made the decision based on the results of the drug’s clinical tests for all three phases.
Celltrion added that the Brazilian health agency also looked into their preclinical studies that show the efficacy of the treatment against COVID-19 variants. Once it is made available in Brazil, Regkirona will be utilized for the treatment of adult patients who are at higher risk from COVID-19 and experiencing both mild and severe symptoms.
Korea Biomedical Review reported that adults aged 65 or older with mild and moderate symptoms would also be treated with Celltrion’s antibody drug. With the high number of daily coronavirus cases in Brazil today, Celltrion said it will deliver Rekirona to the country as fast as it could to help treat the patients.
In the COVID-19 world statistics on Worldometer, Brazil has more than 20 million cases of coronavirus infection and more than 560,000 deaths. With the spread of the more contagious Delta variant, the country is recording daily cases of around 10,000 to 30,000.
“Based on the safety and efficacy proven through large-scale global clinical data of Regkirona, the company has obtained emergency use approval from the Brazilian health authorities,” a Celltrion official stated. “We will do our best to contribute to preventing the spread of Covid-19 by supplying Regkirona early to Brazil, where the number of confirmed cases has recently rapidly increased to 30,000 a day due to the spread of the Delta variant.”
Celltrion declared that its Rekirona antibody treatment drug could reduce the risk of the coronavirus infection from progressing to a severe stage. The pharmaceutical firm further said that it could lessen the recovery time as well. Meanwhile, with the Brazilian EUA, Celltrion is planning to submit an application for similar authorization in the U.S.
